Table 1.
Clinical characteristics of the COVID-19 patients at baseline.
| Characteristic | Total (N = 33) | IFN-κ+TFF2 (N = 11) | Control (N = 22) | p value |
|---|---|---|---|---|
| Male sex-no. (%) | 19(57.6%) | 7(63.6%) | 12(54.5%) | |
| Age median (IQR)-yr | 50(28–58) | 45(28–52.5) | 55.5(28.3–59.8) | 0.33 |
| Underlying diseases: | ||||
| Diabetes no. (%) | 6(18·2%) | 2(18·2%) | 4(18·2%) | |
| Hypertension no. (%) | 5(15·1%) | 0(0·0%) | 5(15·1%) | |
| Hyperlipidnemid no. (%) | 1(3·0%) | 1(9·1%) | 0(0·0%) | |
| Obstrctive sleep apnea-hypopnea syndrome no. (%) | 1(3·0%) | 1(9·1%) | 0(0·0%) | |
| Cough-no. (%) | 23(69.7%) | 8(72.7%) | 15(68.2%) | |
| Ct median (IQR) | 27.3(25.1–31.3) | 28.9(27.5–31.9) | 26.7(23.8–30.6) | 0.25 |
| Body temperature, median (IQR)- °C | 37.5(36.9–38.2) | 37.5(36.8–37.6) | 37.7(37.4–38.3) | 0.1 |
| Fever-no. (%) | 22(78.6%) | 6(60%) | 16(88.9%) | |
| White-cell count (× 109/liter) -median (IQR) | 5.2(4 −6.4) | 6.4(5.4–7.2) | 4.4(3.9–5.8) | 0.04 |
| 4–10 × 109/liter-no. (%) | 26(78.8%) | 10(90.9%) | 16(72.7%) | |
| <4 × 109/liter-no. (%) | 7(21.2%) | 1(9.1%) | 6(27.8%) | |
| >10 × 109/liter-no. (%) | 0(0%) | 0(0%) | 0(0%) | |
| Lymphocyte count (× 109/liter)-median (IQR) | 1.3(1–1.6) | 1.4(1.2–1.9) | 1.2(0.9–1.5) | 0.07 |
| ≥1.0 × 109/liter-no. (%) | 25(75.8%) | 9(81.8%) | 16(72.7%) | |
| <1.0 × 109/liter-no. (%) | 8(24.2%) | 2(18.2%) | 6(27.3%) | |
| Platelet count (× 109/liter)-median (IQR) | 210(166–255) | 210(195.5–257.5) | 208(162.2–247) | 0.91 |
| ≥100 × 109/liter-no. (%) | 28(100%) | 10(100%) | 18(100%) | |
| <100 × 109/liter-no. (%) | 0(0%) | 0(0%) | 0(0%) | |
| Serum creatinine (μmol/liter)-median (IQR) | 70.7(53.2–78.1) | 71.7(50.5–77.7) | 69.4(55.9–82) | 0.39 |
| ≤133 μmol/liter-no. (%) | 32(97%) | 11(100%) | 21 (95.2%) | |
| >133 μmol/liter-no. (%) | 1(3%) | 0(0%) | 1(4.8%) | |
| AST(U/liter)-median (IQR) | 21(17–24) | 19(14–22) | 22(19.3–28) | 0.35 |
| ≤40 U/liter-no. (%) | 30(90.9%) | 10(90.9%) | 20(90.9%) | |
| >40 U/liter-no. (%) | 3(9.1%) | 1(9.1%) | 2(9.1%) | |
| ALT(U/liter)-median (IQR) | 23(15–32) | 21(13.5–31.5) | 25(19.3–31.8) | 0.44 |
| ≤50 U/liter-no. (%) | 29(87.9%) | 10(90.9%) | 19(86.4%) | |
| >50 U/liter-no. (%) | 4(12.1%) | 1(9.1%) | 3(13.6%) | |
| LDH (U/liter)-median (IQR) | 195(172–226) | 182(157–227) | 195.5(175–225.5) | 0.50 |
| ≤245 U/liter-no. (%) | 25(75.8%) | 8(72.7%) | 17(77.3%) | |
| >245 U/liter-no. (%) | 8(24.2%) | 3(27.3%) | 5(22.7%) | |
| CK(U/liter)-median (IQR) | 80(59.8–104.8) | 79(45.5–110.3) | 80(64.8–102.8) | 0.42 |
| ≤185 U/liter-no. (%) | 32(97%) | 11(100%) | 21(95.5%) | |
| >185 U/liter-no. (%) | 1(3%) | 0(0%) | 1(4.5%) |
All enrolled COVID-19 patients were not allergic to aerosol inhalation of IFN-κ plus TFF2, with no serious organ disease, including heart, lung, kidney, brain, blood, and also no serious neurological or mental illness. All female patients were not pregnant. IQR, interquartile range; AST, Aspartate amino transferase; ALT, Alanine amino transferase; LDH, Lactate dehydrogenase; CK, Creatine kinase. P value was evaluated between the control group and IFN-κ plus TFF2 group by unpair t-test. p < 0.05 was denoted as significance.